Purple Biotech (PPBT) Net Income towards Common Stockholders Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Purple Biotech | 3.58 Bn | 3.57 Bn | - | -81.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.02% |
| Dec 31, 2025 | 5,642.93% |
| Sep 30, 2025 | 96.53% |
| Jun 30, 2025 | -55.00% |
| Mar 31, 2025 | -88.01% |
| Dec 31, 2024 | -91.51% |
| Sep 30, 2024 | -86.83% |
| Jun 30, 2024 | -53.08% |
| Mar 31, 2024 | -22.59% |
| Dec 31, 2023 | -19.68% |
| Sep 30, 2023 | 4.39% |
| Jun 30, 2023 | 44.45% |
| Mar 31, 2023 | -33.14% |
| Dec 31, 2022 | 18.51% |
| Sep 30, 2022 | 53.78% |
| Jun 30, 2022 | -1.96% |
| Mar 31, 2022 | 11.46% |
| Dec 31, 2021 | 2,205.45% |
| Dec 31, 2020 | -93.28% |
| Dec 31, 2019 | 838.40% |
| Dec 31, 2018 | -94.59% |
| Dec 31, 2017 | -8.47% |
| Dec 31, 2016 | 60.70% |
| Dec 31, 2015 | 630.67% |
| Sep 30, 2015 | -44.20% |